Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Good Old Fashion Tree Shake
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(598)
•••
Comment by clubhouse19on Dec 16, 2020 4:09pm
183 Views
Post# 32121327

RE:RE:RE:RE:RE:Good Old Fashion Tree Shake

RE:RE:RE:RE:RE:Good Old Fashion Tree ShakeI guess anything is ok to make you feel better..selling before this expected sell off made me feel better.
This sell off isn't overafter such a useless and badly timed reverse split

what was the reason for it again to make it on the big board into the shark tank and the Bay Street brothel ??



crow27 wrote: Could be many things but I am always suspicious when I see this type of trading. Someone always holding it back when it wants to go higher. That is what I call accumulation at discount prices.
FDA approval will change everything and I believe the smart money knows this. We all just want to get it as cheap as possible. Play a few games and get the SP down
Buy on the dips folks.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities